DCM
MNPR icon

Driehaus Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Driehaus Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
33,156
-559
-2% -$33.8K 0.01% 304
2025
Q4 		$2.2M Sell
33,715
-30,921
-48% -$2.53M 0.02% 330
2025
Q3 		$5.28M Buy
+64,636
New +$2.89M 0.04% 320

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Driehaus Capital Management's MNPR Position: Q1 2026 in Review

Driehaus Capital Management reduced its Monopar Therapeutics (MNPR) stake by 1.7% in Q1 2026, selling an estimated $33.8K and leaving 33,156 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #304.

Driehaus Capital Management first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.28M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Driehaus Capital Management held 33,156 shares of Monopar Therapeutics worth $1.82M as of Q1 2026.
  • Driehaus Capital Management sold 559 Monopar Therapeutics shares in Q1 2026, an estimated $33.8K.
  • Monopar Therapeutics made up 0.01% of Driehaus Capital Management's portfolio in Q1 2026, its #304 holding.
  • Driehaus Capital Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Driehaus Capital Management's Monopar Therapeutics position peaked at $5.28M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.